Physician profile
Constance B Maroney
NPI 1821293093
$2,627.42
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $326 · 2021: $402 · 2022: $246 · 2023: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.95 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $762.21 | 2019-2023 | |
| Lilly USA, LLC | $280.61 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $264.69 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $235.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $161.21 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $156.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $148.45 | 2019-2023 | |
| Astellas Pharma US INC | $100.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.05 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $63.75 | 2019-2022 | |
| Pfizer INC. | $51.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.50 | 2019-2021 | |
| Renalytix Ai, INC. | $44.62 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Allergan, INC. | $42.23 | 2020 | |
| Sanofi-Aventis U.S. LLC | $35.40 | 2020-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.81 | 2022 | |
| Daiichi Sankyo INC. | $28.81 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $26.42 | 2023 | Rexulti |
| Radius Health, INC. | $14.75 | 2019 | |
| Amarin Pharma, INC. | $14.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.88 | 2019 | |
| Abbvie INC. | $13.21 | 2023 | |
| Boston Scientific Corporation | $13.07 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Maroney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.